MedTrace Logo

Ultrasound-Guided Dextrose Hydrodissection of the Median Nerve

NCT07371221 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-01-30

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the clinical and ultrasonographic outcomes of ultrasound-guided median nerve hydrodissection with 5% dextrose in patients with mild and moderate carpal tunnel syndrome.

The main questions it aims to answer are:

* Does ultrasound-guided dextrose hydrodissection improve pain and functional status in patients with carpal tunnel syndrome?
* Does this procedure lead to changes in ultrasonographic parameters of the median nerve?
* Is ultrasound-guided dextrose hydrodissection a safe procedure in this patient population?

Participants will:

* Undergo a single session of ultrasound-guided median nerve hydrodissection with 5% dextrose
* Be evaluated before the procedure and at 1-month and 3-month follow-up visits using clinical outcome measures and ultrasound assessment
* Be monitored for any procedure-related adverse events

Conditions

  • Carpal Tunnel Syndrome (CTS)

Interventions

PROCEDURE

Ultrasound-Guided Median Nerve Hydrodissection with 5% Dextrose

This intervention consists of a single-session ultrasound-guided hydrodissection of the median nerve using 5% dextrose solution in patients with mild and moderate carpal tunnel syndrome. The procedure is performed under aseptic conditions by trained physicians using a high-frequency linear ultrasound transducer. Real-time in-plane imaging is used to visualize the median nerve and surrounding structures, and the injectate is administered via an ulnar approach to mechanically separate the median nerve from adjacent connective tissues within the carpal tunnel. Participants are monitored for any procedure-related adverse events during and after the intervention.

Sponsors & Collaborators

  • Dr. Nafiz Korez Sincan State Hospital

    lead OTHER_GOV

Principal Investigators

  • Suheyla Dal Erdogan, Medical Doctor · Dr. Nafiz Korez Sincan State Hospital

  • Sevgi Esra Ozdemir Tekes · Dr. Nafiz Korez Sincan State Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2025-06-26
Completion
2025-06-26

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07371221 on ClinicalTrials.gov